

HOLD TP: Rs 1,350 | A 10%

**BLUE STAR** 

**Consumer Durables** 

04 November 2022

### Best Q2 performer among AC pack

- Q2 unitary product margin up 110bps YoY to 6.2%; management commentary positive, unlike tepid outlook from peers
- Strong, sustained traction in EMP business led by peak order book in a favourable market
- FY23/FY24 EPS pared 4.5%/0.3% to bake in the H1 print; on rollover, our TP rises to Rs 1,350 (vs. Rs 1,100) – retain HOLD

Vinod Chari | Nilesh Patil Tanay Rasal research@bobcaps.in

**Better Q2 despite unfavourable seasonality:** BLSTR reported a relatively stronger Q2FY23 performance than peers with in-line revenue (+27% YoY) and modest margin deterioration vis-à-vis competitors. In addition to robust momentum in electromechanical projects (EMP), a better performance in the unitary cooling product (UCP) vertical boosted overall growth. BLSTR has maintained market share at 13.25% for Q2FY23, expects to add 50bps in FY23 and to close FY24 at 15%.

**UCP** margin expansion a rarity for the quarter: UCP EBIT margin at 6.2% climbed 110bps YoY in Q2 as compared to declines for peers (VOLT: -280bps YoY to 7.3%, Lloyd: -20%). While other players in the air conditioner space expect stress on margins to persist in H2, BLSTR reiterated its optimistic 8-8.5% target for FY23. An expanding distribution footprint and new affordable product range are buoying growth.

**EMP maintains traction:** The EMP business clocked stronger margins as the carried-forward order book scaled to record highs of Rs 4.2bn (vs. Rs 3.2bn in Q2FY22). EMP revenue grew 33% YoY to Rs 9.6bn. The judicious selection of projects offering adequate cash flow during the ongoing construction capex upcycle is fuelling growth. Management forecasts a 20-25% CAGR increase in EMP revenue at 6-6.5% margins over next few years

**Retain HOLD; TP revised to Rs 1,350:** Accounting for H1FY23 numbers, we trim FY23/FY24 EPS estimates marginally by 4.5%/0.3%. On rolling valuations forward to Sep'24E, our TP rises to Rs 1,350 (vs. Rs 1,100), based on an unchanged 38x P/E – a 13% premium to the 5Y average. BLSTR continues to focus on taking growth higher via tactical market share gains and margin expansion. We retain HOLD given limited upside potential, but now prefer BLSTR over VOLT (also rated HOLD, TP Rs 1,000) in light of the company's resilient performance in the cooling business during trying times, management's upbeat outlook and cushioning from robust EMP traction.

#### **Key changes**

Target	Rating	
<b>A</b>	<b>∢</b> ▶	

Ticker/Price	BLSTR IN/Rs 1,223
Market cap	US\$ 1.4bn
Free float	61%
3M ADV	US\$ 1.7mn
52wk high/low	Rs 1,274/Rs 836
Promoter/FPI/DII	39%/12%/23%

Source: NSE | Price as of 4 Nov 2022

# **Key financials**

Y/E 31 Mar	FY22A	FY23E	FY24E
Total revenue (Rs mn)	60,456	69,965	80,341
EBITDA (Rs mn)	3,465	4,074	4,995
Adj. net profit (Rs mn)	1,677	2,369	2,772
Adj. EPS (Rs)	17.4	24.6	28.8
Consensus EPS (Rs)	17.4	27.8	36.1
Adj. ROAE (%)	17.6	21.9	22.6
Adj. P/E (x)	70.2	49.7	42.5
EV/EBITDA (x)	34.0	28.9	23.6
Adj. EPS growth (%)	67.1	41.2	17.0

Source: Company, Bloomberg, BOBCAPS Research

### Stock performance



Source: NSE





Fig 1 - Quarterly performance

Particulars (Rs mn)	Q2FY23	Q2FY22	YoY (%)	Q4FY22	Q1FY23	QoQ (%)	H1FY23	H1FY22	YoY (%)
Revenue	15,762	12,397	27.1	22,476	19,703	(20.0)	35,466	22,918	54.8
EBITDA	856	707	21.1	1,430	1,233	(30.6)	2,089	1,129	85.0
EBITDA Margin (%)	5.4	5.7	(30bps)	6.4	6.3	(80bps)	5.9	4.9	100bps
Depreciation	245	204	-	231	220	-	465	405	-
Interest	121	112	-	129	106	-	227	219	-
Other Income	86	84	-	69	105	-	191	161	-
PBT	576	474	21.4	1,139	1,012	(43.1)	1,587	666	138.3
Tax	149	160	-	376	263	-	412	226	-
Adjusted PAT	426	313	35.9	764	742	(42.7)	1,168	440	165.2
Exceptional item	-	-	-	-	-	-	-	-	-
Reported PAT	426	313	35.9	764	742	(42.7)	1,168	440	165.2
Adj. PAT Margin (%)	2.7	2.5	20bps	3.4	3.8	(110bps)	3.3	1.9	140bps
EPS (Rs)	4.4	3.3	35.7	7.9	7.8	(42.9)	12.2	4.6	167.1

Source: Company, BOBCAPS Research

Fig 2 - Actual vs. Estimates

Particulars (Rs mn)	Actual	BOBCAPS	Variance (%)
Revenue	15,762	15,830	(0.4)
EBITDA	856	1,003	(14.6)
EBITDA Margin (%)	5.4	6.3	(90bps)
Adj. PAT	426	515	(17.3)


Source: Company, BOBCAPS Research

Fig 3 - Peer comparison: UCP business, Q2FY23

Company	EBIT margin	Revenue growth (%)				
Company	(%)	3Y CAGR	Growth YoY	Growth QoQ		
BLSTR – UCP	6.2	12.0	15.0	(53.0)		
VOLT – UCP	7.3	25.9	4.0	(52.0)		
Lloyd – UCP	(20.0)	33.0	21.0	(62.0)		


Source: Company, BOBCAPS Research

Fig 4 - Revenue growth



Source: Company, BOBCAPS Research


Fig 5 - EBITDA growth



Source: Company, BOBCAPS Research




Fig 6 - PAT growth




Source: Company, BOBCAPS Research

Fig 7 - EMP growth




Source: Company, BOBCAPS Research

Fig 8 - UCP growth







Source: Company, BOBCAPS Research | PEIS: Professional Electronics and Industrial Systems

## **Earnings call highlights**

- Outlook: Management is optimistic about H2FY23 prospects led by (1) robust room AC (RAC) demand from the residential segment, (2) its portfolio rejig towards the affordable range (price review in Jan'23), with an increasing thrust on sales to the Hindi-speaking belt, and (3) a strong B2B outlook
- Guidance: BLSTR reiterated its optimistic UCP EBIT margin guidance of 8-8.5% for FY23. In EMP, the government's infrastructure push (water, metro rail and power) is a key positive, though the company is adopting a cautious approach toward project bids. Management has guided for 20-25% revenue growth in EMP with a 6-6.5% operating margin in FY23.

In commercial refrigeration, the company expects to log a 20% CAGR over the next few years led by demand from the food processing and retail sectors, and is focused on holding on to its #1 position in freezers and cold rooms. Air coolers and water purifiers are yet to gain traction.

Price increases: Management will review prices only by Jan'23 as it remains hopeful of supply chain normalisation on the back of a return to stability in China, currency depreciation, and commissioning of the Sri City plant as well as backward integration facilities.

# **BLUE STAR**



- Market share: BLSTR believes low penetration in RACs will aid market share gains. The company is currently at 13.25% and targeting a share of 13.75% by FY23-end and 15%+ by FY24-end.
- **Distribution:** The distribution footprint is being expanded from 7,500 dealers to 10,000 by FY23-end.



# Valuation methodology

Accounting for H1FY23 numbers, we trim FY23/FY24 EPS estimates marginally by 4.5%/0.3%. On rolling valuations forward to Sep'24E, our TP rises to Rs 1,350 (vs. Rs 1,100), based on an unchanged 38x P/E – a 13% premium to the five-year average.

BLSTR continues to focus on taking growth higher via tactical market share gains and margin expansion. We retain HOLD given limited upside potential, but now prefer BLSTR over VOLT (also rated HOLD, TP Rs 1,000) in light of the company's resilient performance in the cooling business during trying times, management's upbeat outlook and cushioning from robust EMP traction.

Fig 10 - Revision in estimates

Particulars (Rs mn)	New		Old		Change	(%)
	FY23E	FY24E	FY23E	FY24E	FY23E	FY24E
Sales	69,965	80,341	70,045	80,432	(0.1)	(0.1)
EBITDA	4,074	4,995	4,225	5,008	(3.6)	(0.2)
PAT	2,369	2,772	2,481	2,781	(4.5)	(0.3)
EPS (Rs)	24.6	28.8	25.8	28.9	(4.5)	(0.3)
EBITDA Margin (%)	5.8	6.2	6.0	6.2	(20bps)	0bps

Source: Company, BOBCAPS Research

# **Key risks**

Key risks to our estimates are:

- Upside risks: Aggressive market share gains
- Downside risks: Inability to maintain momentum in UCP, and below-guided growth

# Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
Amber Enterprises	AMBER IN	0.8	2,020	2,100	HOLD
Blue Star	BLSTR IN	1.4	1,223	1,350	HOLD
Crompton Greaves	CROMPTON IN	2.8	362	500	BUY
Dixon Technologies	DIXON IN	3.3	4,514	5,200	BUY
Havells India	HAVL IN	9.2	1,209	1,500	BUY
Orient Electric	ORIENTEL IN	0.7	263	310	HOLD
Polycab India	POLYCAB IN	5.0	2,729	3,300	BUY
V-Guard Industries	VGRD IN	1.3	255	250	HOLD
Voltas	VOLT IN	3.4	845	1,000	HOLD

Source: BOBCAPS Research, NSE | Price as of 4 Nov 2022



# **Financials**

Income Statement	EV04A	EV004	EV00E	EV04E	LAVE
Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23E	FY24E	FY25E
Total revenue	42,636	60,456	69,965	80,341	93,276
EBITDA	2,398	3,465	4,074	4,995	6,687
Depreciation	923	860	866	1,312	1,330
EBIT	1,475	2,605	3,208	3,683	5,357
Net interest inc./(exp.)	(647)	(464)	(445)	(459)	(477)
Other inc./(exp.)	624	357	393	472	566
Exceptional items	0	0	0	0	0
EBT	1,452	2,498	3,156	3,696	5,446
Income taxes	471	829	795	931	1,372
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	26	11	11	11	11
Reported net profit	1,004	1,677	2,369	2,772	4,081
Adjustments	0	0	0	0	0
Adjusted net profit	1,004	1,677	2,369	2,772	4,081
Balance Sheet					
Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23E	FY24E	FY25E
Accounts payables	16,049	20,417	11,501	13,207	15,333
Other current liabilities	5,301	8,448	9,777	11,227	13,034
Provisions	0,001	0,1.0	0,	0	0,00
Debt funds	4.516	3,003	3,180	3,281	3,407
Other liabilities	223	324	370	421	484
Equity capital	193	193	193	193	193
Reserves & surplus	8.659	9,983	11,292	12,909	15.834
Shareholders' fund	8,852	10,176	11,485	13,101	16,027
Total liab. and equities	34.941	42.368	36,313	41,237	48,284
Cash and cash eq.	6.112	4,147	(10,360)	(11,320)	(12,831)
Accounts receivables	8,110	11,897	13,538	15,678	18,126
Inventories	8,824	11,442	14,951	16,187	19,363
Other current assets	5,549	7,348	8,503	9,764	11,336
Investments	0,549	7,340	0,303	9,704	
Net fixed assets	3,836	4,328	5,962	6,651	7,321
CWIP	681	1,451	1,679	1,928	
	001				2,239
Intangible assets		0	0	0	0
Deferred tax assets, net	0	0		•	0.707
Other assets	1,829	1,755	2,030	2,332	2,707
Total assets	34,941	42,368	36,305	41,221	48,260
Cash Flows					
Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23E	FY24E	FY25E
Cash flow from operations	3,498	918	(10,666)	2,595	2,142
Capital expenditures	174	(2,179)	(2,500)	(2,000)	(2,000)
Change in investments	(2,791)	1,340	0	0	0
Other investing cash flows	232	166	(458)	(500)	(623)
Cash flow from investing	(2,385)	(673)	(2,958)	(2,500)	(2,623)
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	2,968	654	177	101	126
Interest expenses	0	0	0	0	0
Dividends paid	(3,663)	(1,521)	(1,059)	(1,156)	(1,156)
Other financing cash flows	0	0	0	0	Ó
Cash flow from financing	(696)	(868)	(883)	(1,055)	(1,030)
Chg in cash & cash eq.	418	(623)	(14,507)	(960)	(1,511)
Closing cash & cash eq.	6,112	4,147	(10,360)	(11,320)	(12,831)
	₹,112	.,	(10,000)	( , • = • /	( . = ,001)

Per Share					
Y/E 31 Mar (Rs)	FY21A	FY22A	FY23E	FY24E	FY25E
Reported EPS	10.4	17.4	24.6	28.8	42.4
Adjusted EPS	10.4	17.4	24.6	28.8	42.4
Dividend per share	4.0	10.0	11.0	12.0	12.0
Book value per share	91.9	105.7	119.2	136.0	166.4
Valuations Ratios					
Y/E 31 Mar (x)	FY21A	FY22A	FY23E	FY24E	FY25E
EV/Sales	2.8	1.9	1.7	1.5	1.3
EV/EBITDA	49.1	34.0	28.9	23.6	17.6
Adjusted P/E	117.4	70.2	49.7	42.5	28.9
P/BV	13.3	11.6	10.3	9.0	7.3
DuPont Analysis					
Y/E 31 Mar (%)	FY21A	FY22A	FY23E	FY24E	FY25E
Tax burden (Net profit/PBT)	69.1	67.1	75.1	75.0	74.9
Interest burden (PBT/EBIT)	98.4	95.9	98.4	100.3	101.7
EBIT margin (EBIT/Revenue)	3.5	4.3	4.6	4.6	5.7
Asset turnover (Rev./Avg TA)	11.1	14.0	11.7	12.1	12.7
Leverage (Avg TA/Avg Equity)	0.5	0.5	0.6	0.5	0.5
Adjusted ROAE	12.0	17.6	21.9	22.6	28.0
Ratio Analysis					
Y/E 31 Mar	FY21A	FY22A	FY23E	FY24E	FY25E
YoY growth (%)					
Revenue	(20.5)	41.8	15.7	14.8	16.1
EBITDA	(15.2)	44.5	17.6	22.6	33.9
Adjusted EPS	(31.9)	67.1	41.2	17.0	47.2
Profitability & Return ratios (%)					
EBITDA margin	5.6	5.7	5.8	6.2	7.2
EBIT margin	3.5	4.3	4.6	4.6	5.7
Adjusted profit margin	2.4	2.8	3.4	3.5	4.4
Adjusted ROAE	12.0	17.6	21.9	22.6	28.0
ROCE	11.2	14.9	19.4	20.0	24.7
Working capital days (days)					
Receivables	69	72	71	71	71
Inventory	76	69	78	74	76
Payables	137	123	60	60	60
Ratios (x)					
Gross asset turnover	5.8	7.6	7.1	6.7	6.6

1.2

5.6

0.3

1.2

7.2

0.3

1.3

2.3

0.5

1.2

8.0

0.3

1.2

11.2

0.2

Adjusted debt/equity Source: Company, BOBCAPS Research | Note: TA = Total Assets

Current ratio

Net interest coverage ratio



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

### Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

### Ratings and Target Price (3-year history): BLUE STAR (BLSTR IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

#### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017. BOBCAPS CIN Number: U65999MH1996GOI098009.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

### **BLUE STAR**



We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. Research analyst Vinod Chari has 875 shares of Voltas (VOLT IN). BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

### Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

#### Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.